Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 44.60% is in line with its 5-year average of 48.64%, near the low end of its 5-year range (42.56%–76.84%).
0.08% above its 12-month average of 44.57%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-28): 43.26%.
GROSS MARGIN
44.60%
GROSS MARGIN AVG TTM
44.57%
GROSS MARGIN AVG 3Y
46.35%
GROSS MARGIN AVG 5Y
48.64%
GROSS MARGIN AVG 10Y
57.44%
GROSS MARGIN AVG 15Y
58.14%
GROSS MARGIN AVG 20Y
58.16%
CURRENT VS TTM AVG
+0.08%
CURRENT VS 3Y AVG
-3.77%
CURRENT VS 5Y AVG
-8.31%
CURRENT VS 10Y AVG
-22.35%
CURRENT VS 15Y AVG
-23.28%
CURRENT VS 20Y AVG
-23.31%
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+8.24%
vs the sector median at left
QuidelOrtho Corporation
Market Cap
$857.16M
Gross Margin
44.60%
TTM Avg
44.57%
3Y Avg
46.35%
5Y Avg
48.64%
Market Cap
$853.13M
Gross Margin
91.39%
TTM Avg
91.47%
3Y Avg
93.85%
5Y Avg
95.64%
Market Cap
$852.35M
Gross Margin
35.27%
TTM Avg
46.37%
3Y Avg
58.90%
5Y Avg
58.90%
Market Cap
$870.81M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$838.62M
Gross Margin
35.97%
TTM Avg
27.94%
3Y Avg
30.11%
5Y Avg
34.47%
Market Cap
$838.16M
Gross Margin
58.31%
TTM Avg
55.25%
3Y Avg
65.77%
5Y Avg
65.77%
Market Cap
$833.81M
Gross Margin
92.94%
TTM Avg
91.25%
3Y Avg
45.63%
5Y Avg
30.42%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| QuidelOrtho Corporation (QDEL) | $857.16M | 44.60% | 44.57% | 46.35% | 48.64% |
| Alumis Inc. (ALMS)vs › | $855.38M | 88.23% | 42.73% | 21.36% | 21.36% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 91.39% | 91.47% | 93.85% | 95.64% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | 35.27% | 46.37% | 58.90% | 58.90% |
| SI-BONE, Inc. (SIBN)vs › | $867.03M | 79.53% | 79.30% | 80.66% | 83.15% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | 100.00% | 100.00% | 100.00% | 100.00% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | 35.97% | 27.94% | 30.11% | 34.47% |
| Beta Bionics, Inc. (BBNX)vs › | $838.16M | 58.31% | 55.25% | 65.77% | 65.77% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $833.81M | 92.94% | 91.25% | 45.63% | 30.42% |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | 99.98% | 98.71% | 99.36% | -14.89% |
Gross Margin
44.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-28 | 43.26% |
| 2026-03-29 | 42.56% |
| 2025-12-28 | 44.28% |
| 2025-09-28 | 47.95% |
| 2025-06-29 | 44.78% |
| 2025-03-30 | 49.55% |
| 2024-12-29 | 46.07% |
| 2024-09-29 | 48.45% |
| 2024-06-30 | 43.33% |
| 2024-03-31 | 46.71% |
| 2023-12-31 | 51.35% |
| 2023-10-01 | 49.65% |
| 2023-07-02 | 44.58% |
| 2023-04-02 | 53.02% |
| 2023-01-01 | 51.82% |
| 2022-10-02 | 51.99% |
| 2022-07-03 | 55.02% |
| 2022-03-31 | 74.03% |
| 2021-12-31 | 76.84% |
| 2021-09-30 | 73.64% |
| 2021-06-30 | 61.16% |
| 2021-03-31 | 80.45% |
| 2020-12-31 | 86.69% |
| 2020-09-30 | 80.58% |
| 2020-06-30 | 73.73% |
| 2020-03-31 | 65.84% |
| 2019-12-31 | 62.32% |
| 2019-09-30 | 59.97% |
| 2019-06-30 | 54.67% |
| 2019-03-31 | 61.45% |
| 2018-12-31 | 61.95% |
| 2018-09-30 | 59.32% |
| 2018-06-30 | 55.90% |
| 2018-03-31 | 62.83% |
| 2017-12-31 | 51.46% |
| 2017-09-30 | 61.90% |
| 2017-06-30 | 53.60% |
| 2017-03-31 | 68.02% |
| 2016-12-31 | 63.80% |
| 2016-09-30 | 64.07% |
| 2016-06-30 | 55.75% |
| 2016-03-31 | 61.75% |
| 2015-12-31 | 65.42% |
| 2015-09-30 | 63.77% |
| 2015-06-30 | 55.57% |
| 2015-03-31 | 65.56% |
| 2014-12-31 | 66.57% |
| 2014-09-30 | 58.96% |
| 2014-06-30 | 49.50% |
| 2014-03-31 | 56.62% |
| 2013-12-31 | 62.77% |
| 2013-09-30 | 54.39% |
| 2013-06-30 | 53.98% |
| 2013-03-31 | 68.47% |
| 2012-12-31 | 67.37% |
| 2012-09-30 | 54.93% |
| 2012-06-30 | 54.60% |
| 2012-03-31 | 60.99% |
| 2011-12-31 | 60.18% |
| 2011-09-30 | 54.71% |
| 2011-06-30 | 54.41% |
| 2011-03-31 | 66.37% |
| 2010-12-31 | 56.44% |
| 2010-09-30 | 54.63% |
| 2010-06-30 | 49.51% |
| 2010-03-31 | 52.95% |
| 2009-12-31 | 71.40% |
| 2009-09-30 | 68.53% |
| 2009-06-30 | 59.12% |
| 2009-03-31 | 50.12% |
| 2008-12-31 | 58.88% |
| 2008-09-30 | 62.13% |
| 2008-06-30 | 53.27% |
| 2008-03-31 | 65.43% |
| 2007-12-31 | 60.12% |
| 2007-09-30 | 59.52% |
| 2007-06-30 | 49.86% |
| 2007-03-31 | 61.83% |
| 2006-12-31 | 60.56% |
| 2006-09-30 | 56.39% |
| 2006-06-30 | 47.37% |
| 2006-03-31 | 61.13% |
| 2005-12-31 | 63.11% |
| 2005-09-30 | 53.67% |
| 2005-06-30 | 55.32% |
| 2005-03-31 | 63.09% |
| 2004-12-31 | 64.43% |
| 2004-09-30 | 46.52% |
| 2004-06-30 | 48.13% |
| 2004-03-31 | 52.37% |
| 2003-12-31 | 60.13% |
| 2003-09-30 | 50.81% |
| 2003-06-30 | 50.80% |
| 2003-03-31 | 54.40% |
| 2002-12-31 | 50.65% |
| 2002-09-30 | 45.53% |
